Exact Sciences Corporation EXAS has launched the Cancerguard test, a new multi-cancer early detection (MCED) blood test now offered as a laboratory-developed test (LDT) in the United States.

SEATTLE, July 31, 2024 /PRNewswire/ -- TwinStrand Biosciences today announced an agreement with Exact Sciences (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, to ...

Exact Sciences (EXAS) announced the launch of the Cancerguard test, a new multi-cancer early detection, or MCED, blood test that is now available ...

(1) Represents stock-based compensation expense and 401(k) match expense. The Company matches a portion of Exact Sciences employees’ contributions annually in the form of the Company’s common stock.

Tevogen (TVGN) Bio provided additional guidance on the first clinical product of the company’s proprietary ExacTcell technology, TVGN 489, designed to treat SARS-CoV-2 infections in immunocompromised ...